Incyte Corp
NASDAQ:INCY
Incyte Corp
NASDAQ:INCY
Price:
57.18 USD
0.56%
Market Closed
Updated:
May 17, 2024
Incyte Corp
Income from Continuing Operations
|
Incyte Corp
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Incyte Corp
NASDAQ:INCY
|
Income from Continuing Operations
$745.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Incyte Corp's Income from Continuing Operations?
Income from Continuing Operations
745.4m
USD
745.4m
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Income from Continuing Operations amounts to 745.4m USD.
What is Incyte Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
24%
24%
Over the last year, the Income from Continuing Operations growth was 130%. The average annual Income from Continuing Operations growth rates for Incyte Corp have been 16% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
